RDA™ Evolves into Platform Technology
While the primary focus of RNA Disruption Assay (RDA) continues to be breast cancer chemotherapy management, it is rapidly evolving into a platform technology that will be utilized in the management of treatments across multiple cancers. RDA is now being employed […]
Rna Diagnostics was awarded first place in the RESI Innovation Challenge held in Boston, Massachusetts on September 16, 2015. The RESI Investor conference included an Innovation Challenge featuring 30 of the most innovative early stage life science companies selected from over 250 biotech, medtech and […]
Rna Diagnostics announces the study, Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy, recently published in Breast Cancer Research and Treatment.
Rna Diagnostics is a Canadian cancer diagnostics company developing diagnostic tools to improve chemotherapy management. The company’s first product, RDA, evaluates early in a woman’s […]
RNA Diagnostics, a Sudbury-based medical diagnostic company, has successfully closed an additional round of angel investment with support of the NORCAT Innovation Mill Angel group.
RNA Diagnostics, with their patented RNA Disruption Assay™ (RDA™), enables clinicians to identify patients who are not responding to chemotherapy early […]
NORCAT’s Innovation Mill helps accelerate the growth of innovative companies like Rna Diagnostics. View clip
NORCAT’s Innovation Mill helps accelerate the growth of innovative companies like Rna Diagnostics. View clip
Interactive cost benefit model shows use of RDA in the neoadjuvant setting cost effective for German payers.
Breast cancer stakeholders attended the 34th Annual Meeting of the German Society for Senology conference featuring up-to-date breast cancer diagnostics and therapies. RDA was represented there via Assessment in […]
Rna Diagnostics hosted a symposium with leading breast cancer researchers and clinical specialists in the UK.
The symposium, chaired by Professor Charles Coombes, Medical Oncology, Imperial College, London on May 22, at the Canadian High Commission in London, brought together leading breast cancer Researchers and Clinical […]
The utility of Rna Diagnostics’ RDA™ (Rna Disruption Assay) test in assessing the effect of chemotherapy drugs has been further illustrated in research just published by Toronto biopharma company Armour Therapeutics. The study entitled “Relaxin antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts” was […]
The utility of Rna Diagnostics’ RDA™ (Rna Disruption Assay) test in assessing the effect of chemotherapy drugs has been further illustrated in research just published by Toronto biopharma company Armour Therapeutics. The study entitled “Relaxin antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts” was […]
